SGLT2抑制剂在成人Alport综合征中的应用
随访约24.5个月后,慢性eGFR斜率显著改善,时间平均蛋白尿下降24.1%,提示SGLT2i可能具有肾脏保护作用。
要点
- 加用SGLT2i后慢性eGFR斜率由-3.48改善至+0.72 ml/min per 1.73 m2/yr
- 时间平均蛋白尿下降24.1%,蛋白尿斜率亦改善
- 杂合COL4A3/COL4A4携带者、正常BMI及肾功能保留者反应一致
核心结论
- 真实世界研究提示SGLT2i对成人Alport综合征可能具有肾脏保护作用,包括杂合COL4A3/COL4A4携带者。
- 获益似乎不依赖基线BMI和肾功能,支持考虑更早启动治疗。
- 上述发现需前瞻性研究验证并细化治疗时机。
研究设计与样本
- 患者均有显著蛋白尿,接受RASi联合SGLT2i治疗,并与此前十年稳定RASi单药治疗期纵向比较。
主要发现
- 随访24.5 ± 13.5个月,慢性eGFR斜率由-3.48改善至+0.72 ml/min per 1.73 m2/yr(P < 0.001)。
- 时间平均蛋白尿下降24.1%(P = 0.005),纵向蛋白尿斜率改善(P = 0.038)。
- 亚组分析显示杂合COL4A3/COL4A4携带者、正常BMI及肾功能保留患者反应一致。
- 次要效应包括血红蛋白和碳酸氢盐升高,以及血尿酸下降和体重减轻。
- 发生3例非严重不良事件,无患者进展至肾衰竭。
关键数值与推荐
- 基线平均年龄54.3 ± 15.4岁,基线eGFR 61.9 ± 26.5 ml/min per 1.73 m2。
- 基线蛋白尿中位数1010.0(521.8-1662.5)mg/g。
临床怎么用
- 对经基因确诊、有明显蛋白尿的成人Alport综合征患者,可在RASi基础上考虑加用SGLT2i。
- 治疗中可监测eGFR斜率、蛋白尿、血红蛋白、碳酸氢盐、血尿酸及体重变化。
局限性
- 需前瞻性研究验证疗效并明确最佳启动时机。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Alport syndrome (AS) is a genetically heterogenous kidney disease characterized by microhematuria, proteinuria, and progressive chronic kidney disease (CKD). Although early renin-angiotensin system inhibitors (RASi) are standard of care, evidence on sodium-glucose cotransporter-2 inhibitors (SGLT2i) in AS is limited. Thus, this study evaluated SGLT2i effects in adult patients with AS. METHODS: We conducted a retrospective, observational study, including patients with genetically confirmed AS with significant proteinuria treated with combined RASi + SGLT2i. Clinico-laboratory data were collected longitudinally and compared with the preceding decade on stable RASi alone. Chronic estimated glomerular filtration rate (eGFR) and proteinuria slopes, changes in time-averaged proteinuria, subgroups responses, and secondary SGLT2i effects were assessed. RESULTS: Eighteen adult patients with AS (mean age: 54.3 ± 15.4 years; baseline eGFR: 61.9 ± 26.5 ml/min per 1.73 m2; median proteinuria: 1010.0 [521.8-1662.5] mg/g) initiated RASi + SGLT2i therapy. Over 24.5 ± 13.5 months, the chronic eGFR slope improved significantly (-3.48 to +0.72 ml/min per 1.73 m2/yr, P < 0.001). Time-averaged proteinuria decreased by 24.1% (P = 0.005), and longitudinal proteinuria slope improved (P = 0.038). Subgroup analyses confirmed consistent responses among patients with heterozygous COL4A3/COL4A4 carriers, normal body mass index (BMI), and preserved renal function. Secondary effects included increases in hemoglobin and bicarbonate, alongside reduction in serum uric acid and weight loss. Three nonserious adverse events occurred, and no patient progressed to kidney failure (KF). CONCLUSION: This real-world study suggests a potential nephroprotective role of SGLT2i in adult patients with AS, including heterozygous COL4A3/COL4A4 carriers. Benefits appeared independent of baseline BMI and renal function, supporting consideration of earlier initiation. Prospective studies are required to validate these findings and refine treatment timing.
引用
- Toso D, Cinquina V, Econimo L, et al. Sodium-Glucose Cotransporter-2-inhibitors in Adult Patients With Alport Syndrome. Kidney Int Rep. 2026. PMID: 42006198. doi:10.1016/j.ekir.2026.106417
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。